This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carmines, P. K. Articles by Fujiwara, K. Search for Related Content PubMed PubMed Citation Articles by Carmines, P. K. Articles by Fujiwara, K. Related Collections ACE/Angiotension receptors Cell signalling/signal transduction Growth factors/cytokines Other Vascular biology

(Hypertension. 2001;37:569.)
© 2001 American Heart Association, Inc.

Scientific Contributions

Tyrosine Kinase Involvement in Renal Arteriolar Constrictor Responses to Angiotensin II

Pamela K. Carmines; Rachel W. Fallet; Qi Che; Keiji Fujiwara

From the Department of Physiology and Biophysics, University of Nebraska Medical Center, Omaha.

Correspondence to Pamela K. Carmines, PhD, Department of Physiology and Biophysics, University of Nebraska College of Medicine, 984575 Nebraska Medical Center, Omaha, NE 68198-4575. E-mail pkcarmin{at}unmc.edu

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Experiments were performed to test the hypothesis that tyrosine kinase activity contributes to renal arteriolar contractile responses to angiotensin (Ang) II. Rats were subjected to short-term enalaprilat treatment to decrease endogenous Ang II formation before tissue was harvested for experiments with the in vitro blood-perfused juxtamedullary nephron technique. Acute surgical papillectomy was used to avoid the indirect afferent arteriolar effect of Ang II that arises through increased tubuloglomerular feedback sensitivity. Arteriolar lumen diameter responses to 1 and 10 nmol/L Ang II were monitored by videomicroscopic methods before and during treatment with various tyrphostin compounds: 100 µmol/L AG18 (broad-spectrum tyrosine kinase inhibitor), 100 nmol/L AG1478 (selective epidermal growth factor receptor tyrosine kinase inhibitor), or 100 µmol/L AG9 (inactive analog). Baseline afferent arteriolar lumen diameter averaged 23.5±1.2 µm and was not influenced by any tyrphostin. Ang II (10 nmol/L) decreased afferent diameter by 11.1±1.0 µm under untreated conditions, a response that was not altered by AG9 but significantly blunted by AG18 (34±9% inhibition) or AG1478 (52±8% inhibition). AG18 did not suppress afferent arteriolar contractile responses to membrane depolarization (20 to 55 mmol/L K⁺ bath). Efferent arteriolar baseline diameter averaged 24.1±0.8 µm and was unaltered by AG18 or AG1478; however, efferent diameter responses to 10 nmol/L Ang II were diminished 52±10% by AG18 and 51±13% by AG1478. These observations indicate that Ang II signaling in renal afferent and efferent arteriolar vascular smooth muscle is either mediated or modulated by tyrosine kinase activity, including that of the epidermal growth factor receptor tyrosine kinase.

Key Words: arterioles • angiotensin II • kinase • receptors

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Although the G-protein–coupled angiotensin (Ang) II type 1 (AT₁) receptor lacks intrinsic tyrosine kinase activity, Ang II binding to this receptor induces tyrosine phosphorylation of multiple signaling proteins. Tyrosine phosphorylation of phospholipase C (PLC)- has been reported to be necessary for Ang II–stimulated inositol trisphosphate (IP₃) formation, Ca²⁺ mobilization, and contraction of mesangial and aortic smooth muscle cells.^{1 2} Moreover, transactivation of the epidermal growth factor (EGF) receptor is evident in vascular smooth muscle within 1 to 2 minutes of Ang II exposure,^{3 4} consistent with the possibility that this process may contribute to the vasoconstrictor response to the peptide. Similarly, Ang II–induced activation of p38 mitogen-activated protein (MAP) kinase occurs within 5 minutes, and inhibition of p38 kinase activity reduces the contractile effect of Ang II on rat aortic rings.⁵ Nevertheless, Watts and colleagues⁶ have demonstrated dissociation of Ang II–induced tyrosine kinase activity from the contractile response of rat aortic rings.

Virtually all studies probing the involvement of tyrosine kinase activity in Ang II activation of vascular smooth muscle have used large arteries or cultured myocytes from these vessels. The involvement of tyrosine kinase activity in evoking Ang II–induced contraction within the microvasculature, including that of the kidney, remains virtually unexplored. Accordingly, the present experiments addressed the hypothesis that tyrosine phosphorylation participates in the renal arteriolar constrictor response to Ang II. Tyrosine kinase activity has also been reported to modulate L-type voltage-gated Ca²⁺ channels. In particular, tonic phosphorylation by tyrosine kinases has been suggested to maintain the channels in an available state for activation by depolarization.⁷ These channels are functionally prominent in the afferent arteriole and represent a critical component of the constrictor response to Ang II in this vascular segment.^{8 9 10 11} Accordingly, we also assessed the influence of tyrosine kinase activity on the afferent arteriolar contractile response to membrane depolarization.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Animals
The procedures used in this study were approved by the University of Nebraska Medical Center Institutional Animal Care and Use Committee and conducted according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Thirty-two male Sprague-Dawley rats (SAS:VAF strain) weighing 250 to 300 g were purchased from Charles River Laboratories and provided free access to food and water before study.

In Vitro Blood-Perfused Juxtamedullary Nephron Technique
Arteriolar contractile function was assessed in experiments performed with the in vitro blood-perfused juxtamedullary nephron technique.¹² After anesthetization with sodium pentobarbital (50 mg/kg IP), a cannula was inserted into the left carotid artery and enalaprilat was administered (2 mg in 1 mL isotonic saline) to reduce endogenous Ang II formation. The left renal artery and vein were ligated and the right renal artery was cannulated through the superior mesenteric artery, thereby initiating renal perfusion with Tyrode’s solution containing 52 g/L dialyzed BSA and a mixture of L-amino acids.¹³ Blood was collected through the carotid cannula before harvesting the kidney. Renal perfusion was maintained throughout the ensuing dissection procedure needed to reveal the tubules, glomeruli, and related vasculature of juxtamedullary nephrons. Tight ligatures were placed around the most distal accessible segments of the large arterial branches that supply the exposed microvasculature. Acute surgical papillectomy was performed to avoid an indirect, tubuloglomerular feedback–dependent influence of Ang II on the vasculature.¹⁴ The Tyrode’s perfusate was then replaced with reconstituted blood prepared as described previously.¹³ Renal arterial perfusion pressure was set at 110 mm Hg and maintained at that level throughout the experiment. The perfusion chamber was warmed, and the tissue surface was bathed continuously with Tyrode’s solution containing 10 g/L BSA at 37°C.

The tissue was transilluminated on the fixed stage of a compound microscope equipped with a water-immersion objective (x40). Video images of the microvessels were stored on videotape for later analysis. An afferent or efferent arteriole was selected for study, based on visibility and acceptable blood flow. All protocols assessed arteriolar diameter at a single measurement site under several experimental conditions. Afferent arteriolar diameter was monitored at sites 100 µm upstream from the glomerulus, whereas efferent arterioles were studied at sites 100 µm from the point of emergence from the glomerulus.

Protocols
Effect of Tyrosine Kinase Blockade on Renal Arteriolar Constrictor Responses to Ang II
After a 15-minute stabilization period, afferent or efferent arteriolar baseline diameter was established during an initial 5-minute control period, after which the effects of exogenous Ang II were assessed. Because Ang II causes similar afferent arteriolar constrictor responses when administered from the bath and lumen of in vitro–perfused juxtamedullary nephrons,¹⁵ the present studies used the technically simpler method of administering the peptide (1 and 10 nmol/L; 3-minute treatment periods) through the bathing solution. After a 10-minute recovery period, 100 µmol/L tyrphostin AG18 (broad-spectrum tyrosine kinase blocker) was added to the perfusate bath. Ten minutes later, the Ang II exposure sequence was repeated. In other experiments, AG18 was replaced with either 100 µmol/L AG9 (inactive analog) or 100 nmol/L AG1478 (EGF receptor tyrosine kinase blocker). Previous studies from our laboratory have documented the stability of juxtamedullary afferent arteriolar lumen diameter in tissue not exposed to exogenous vasoactive agents for the duration of these experiments.^{16 17}

Effect of Tyrosine Kinase Blockade on Afferent Arteriolar Responses to Depolarization
After the stabilization period, baseline afferent arteriolar diameter was established during exposure to the normal bathing solution (Tyrode’s solution containing 2.7 mmol/L K⁺). Subsequently, arteriolar diameter responses to increasing extracellular [K⁺] were assessed (20, 40, and 55 mmol/L K⁺ bath; substitution for Na⁺). After recovery from K⁺-induced depolarization, 100 µmol/L AG18 was added to the bath (10 minutes) and arteriolar responses to increasing bath [K⁺] were repeated in the continued presence of AG18.

Data Analysis
Microvessel inside diameters were measured from videotaped images by a digital image-shearing monitor (model 908, IPM) calibrated with a stage micrometer, a system that allows diameter measurements reproducible to within <1 µm. Microvessel diameter was measured at 12-second intervals from a single site along the vessel length. The average diameter during the final minute of each treatment period was used for statistical analysis (ANOVA for repeated measures and Newman-Keuls tests). Probability values <0.05 were considered significant. All data are reported as mean±SEM (n=number of arterioles).

	Results

Top Abstract Introduction Methods Results Discussion References

 
Effect of Tyrosine Kinase Blockade on Renal Arteriolar Constrictor Responses to Ang II
Figure 1A illustrates the impact of tyrosine kinase blockade on afferent arteriolar lumen diameter responses to Ang II. Baseline afferent arteriolar diameter averaged 23.1±2.0 µm (n=5) and decreased by 3.4±1.5 and 12.7±2.1 µm on exposure to 1 and 10 nmol/L Ang II, respectively. Removal of Ang II from the bath allowed restoration of afferent diameter to 24.0±2.9 µm (P>0.05 versus baseline). Although AG18 (100 µmol/L) alone did not significantly alter baseline afferent diameter (23.9±2.6 µm), 1 and 10 nmol/L Ang II decreased lumen diameter by only 1.9±0.7 and 8.2±1.5 µm (P<0.05 versus untreated), respectively, during AG18 treatment. Thus, exposure to the broad-spectrum tyrosine kinase blocker reduced afferent arteriolar responsiveness to 10 nmol/L Ang II by 34±9%. However, the time required to develop 50% of the peak response to 10 nmol/L Ang II (t₅₀) was unaffected by AG18, averaging 39±7 seconds before and 47±4 seconds during AG18 treatment (P=0.32 by paired t test).

View larger version (22K): [in this window] [in a new window]   Figure 1. Effect of tyrosine kinase blockade on renal arteriolar constrictor responses to Ang II. A, Afferent arteriole; B, efferent arteriole. See text for baseline values. Solid symbols, untreated; open symbols, 100 µmol/L AG18. Data are mean±SEM. *P<0.05 vs baseline (0 nmol/L Ang II); P <0.05, untreated vs AG18.

AG18 also attenuated efferent arteriolar Ang II responsiveness (Figure 1B). Efferent arteriolar lumen diameter averaged 23.6±1.1 µm (n=6) during the untreated baseline period. Ang II evoked reductions in efferent diameter, with 1 nmol/L Ang II decreasing the diameter by 0.7±0.2 µm and 10 nmol/L Ang II decreasing the diameter by 5.0±0.9 µm. Recovery from the Ang II exposure restored efferent diameter to 22.5±1.1 µm (P>0.05 versus baseline). AG18 did not significantly alter efferent arteriolar baseline diameter (22.4±1.1 µm); however, responses to Ang II were attenuated such that 10 nmol/L Ang II only reduced efferent diameter by 2.6±0.6 µm (P<0.005 versus untreated). Thus, tyrosine kinase blockade suppressed the efferent constrictor response to 10 nmol/L Ang II by 52±10%. Values for t₅₀ averaged 38±8 seconds before and 43±17 seconds during AG18 treatment in efferent arterioles (P=0.82 by paired t test), indicating no change in the time course of the response to 10 nmol/L Ang II.

Figure 2A depicts the impact of EGF receptor tyrosine kinase blockade on Ang II–induced afferent arteriolar constriction. Afferent lumen diameter averaged 22.3±1.5 µm (n=7) under baseline conditions, and 1 and 10 nmol/L Ang II reduced afferent diameter by 2.4±0.5 and 9.9±1.0 µm, respectively. Removal of Ang II from the bath allowed restoration of arteriolar diameter to 22.5±1.5 µm. AG1478 (100 nmol/L) did not alter baseline afferent arteriolar diameter (22.6±1.6 µm) but suppressed Ang II–induced vasoconstriction. During exposure to AG1478, 1 and 10 nmol/L Ang II reduced afferent diameter by 0.8±0.7 and 4.5±0.7 µm (P<0.001 versus untreated), respectively. Thus, blockade of the EGF receptor tyrosine kinase inhibited the afferent arteriolar response to 10 nmol/L Ang II by 52±8%.

View larger version (22K): [in this window] [in a new window]   Figure 2. Effect of EGF receptor tyrosine kinase blockade on renal arteriolar constrictor responses to Ang II. A, Afferent arteriole; B, efferent arteriole. See text for baseline values. Solid symbols, untreated; open symbols, 100 nmol/L AG1478. Data are mean±SEM. *P<0.05 vs baseline (0 nmol/L Ang II); P <0.05, untreated vs AG1478.

The effect of EGF receptor blockade on efferent arteriolar responsiveness to Ang II is summarized in Figure 2B. Efferent arteriolar diameter averaged 24.6±1.2 µm (n=7) under baseline conditions and decreased significantly by 1.9±0.5 and 4.6±0.4 µm in response to 1 and 10 nmol/L Ang II, respectively. During recovery from Ang II treatment, efferent arteriolar diameter was restored to 23.8±1.3 µm (P>0.05 versus baseline). AG1478 (100 nmol/L) did not significantly alter baseline efferent diameter (23.3±1.5 µm); however, during continued exposure to AG1478, 1 nmol/L Ang II failed to alter lumen diameter (=-0.3±0.3 µm) and 10 nmol/L Ang II only reduced diameter by 2.1±0.5 µm (P<0.05 versus untreated). Thus, the EGF receptor tyrosine kinase blocker reduced efferent arteriolar responsiveness to 10 nmol/L Ang II by 51±13%.

The effect of the inactive tyrphostin (AG9) on afferent arteriolar diameter responses to exogenous Ang II is depicted in Figure 3A. Afferent arteriolar diameter averaged 22.7±1.8 µm (n=4) under baseline conditions and decreased by 3.9±1.4 and 11.2±2.5 µm during exposure to 1 and 10 nmol/L Ang II, respectively. During the recovery period, afferent lumen diameter returned to 21.8±2.2 µm (P>0.05 versus untreated baseline). AG9 (100 µmol/L) did not alter baseline diameter (22.7±2.2 µm) or responsiveness to Ang II (1 nmol/L, =-3.3±0.8 µm; 10 nmol/L, =-9.9±2.3 µm).

View larger version (25K): [in this window] [in a new window]   Figure 3. Specificity of tyrphostin effects on afferent arteriolar contractile responses. A, Effect of inactive tyrphostin analog on afferent arteriolar responses to Ang II; B, effect of tyrosine kinase blockade on afferent arteriolar responses to K+-induced depolarization. Data are expressed as mean±SEM. Solid symbols, untreated; open symbols, 100 µmol/L AG9 (A) or 100 µmol/L AG18 (B). Data are mean±SEM. *P<0.05 vs baseline (A, 0 nmol/L Ang II; B, 2.7 mmol/L K+).

Effect of Tyrosine Kinase Blockade on Afferent Arteriolar Responses to Depolarization
Figure 3B illustrates the impact of increases in bath [K⁺] on afferent arteriolar diameter before and during tyrosine kinase blockade (100 µmol/L AG18). Afferent diameter averaged 22.5±2.1 µm (n=5) under untreated baseline conditions (2.7 mmol/L K⁺) and was significantly reduced by 40 mmol/L K⁺ (=-10.1±3.3 µm) and 55 mmol/L K⁺ (=-15.5±2.9 µm). Restoration of bath [K⁺] to 2.7 mmol/L allowed full recovery of afferent diameter to baseline values (22.5±2.1 µm). AG18 did not significantly alter baseline diameter (22.5±2.1 µm) or responses to K⁺-induced depolarization (40 mmol/L K⁺, =-10.4±3.2 µm; 55 mmol/L K⁺, =-14.2±2.2 µm).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
In both afferent and efferent arterioles, Ang II induces constriction through its interaction with AT₁ receptors¹⁸ ; however, disparate intracellular signaling events are used by these vascular segments to generate the increase in intracellular Ca²⁺ concentration necessary to produce vasoconstriction. Available evidence indicates that activation of AT₁ receptors in the afferent arteriole activates PLC to elicit IP₃-dependent Ca²⁺ mobilization, resulting in a rise in intracellular [Ca²⁺] that increases the open probability of Ca²⁺-activated Cl^- channels, with the subsequent membrane depolarization prompting Ca²⁺ influx through voltage-gated channels.^{8 19 20} In contrast, activation of efferent arteriolar AT₁ receptors appears to trigger activation of PLC to provoke Ca²⁺ mobilization and protein kinase C–dependent Ca²⁺ influx through a voltage-independent mechanism, possibly through store-operated Ca²⁺ channels.^{11 19 20} The present study used a pharmacological approach to implicate tyrosine phosphorylation in the Ang II–induced signaling events of both afferent and efferent arterioles.

The role of tyrosine phosphorylation in Ang II–induced constriction was assessed through the use of synthetic tyrphostin compounds with characteristic effects on tyrosine kinase activity. AG18, also known as tyrphostin A23, is a broad-spectrum tyrosine kinase inhibitor that blocks EGF receptor autophosphorylation and platelet-derived growth factor receptor kinase with IC₅₀ values in the range of 25 to 40 µmol/L.^{21 22} Because AG18 inhibition of EGF receptor protein kinase is maximally effective at a concentration of 100 µmol/L,²³ this concentration was used in the present study. AG1478 is a potent and specific EGF receptor tyrosine kinase inhibitor (IC₅₀=3 nmol/L), affecting platelet-derived growth factor receptor kinase activity only at much higher concentrations (IC₅₀>100 µmol/L).²⁴ At concentrations within the range of 100 to 250 nmol/L, AG1478 markedly abates EGF-stimulated and Ang II–stimulated increases in MAP kinase activity in rat aortic smooth muscle.⁴ AG9, also known as tyrphostin A1, is an inactive compound used as a negative control (IC₅₀>1250 µmol/L for EGF receptor kinase).²⁵

None of the tyrphostin compounds used in this study significantly altered baseline diameter of afferent or efferent arterioles; however, AG18 attenuated both afferent and efferent arteriolar constrictor responses to Ang II. The failure of the inactive tyrphostin analog to alter afferent arteriolar Ang II responsiveness is consistent with the contention that AG18 suppressed Ang II responsiveness through its ability to inhibit tyrosine kinase activity rather than through a nonspecific effect of tyrphostin compounds. These observations are in accord with reports that tyrosine kinase blockade attenuates Ang II–induced pH_i, intracellular [Ca²⁺], and/or contractile responses in vascular smooth muscle from aorta or mesenteric artery.^{26 27 28}

Tyrphostin compounds have been reported to inhibit L-type voltage-gated Ca²⁺ channels, either secondary to tyrosine kinase blockade^{7 29} or through a direct nonspecific (tyrosine kinase–independent) effect on channel activity.³⁰ Because these channels are prominent in the renal afferent arteriole^{9 10} and in evoking the vasoconstrictor response of this vessel to Ang II,⁸ we assessed the impact of AG18 on K⁺-induced vasoconstriction. Increases in extracellular [K⁺] contract vascular smooth muscle through the effect of membrane depolarization to increase the open probability of L-type Ca²⁺ channels. We have shown previously that the afferent arteriolar intracellular [Ca²⁺] and constrictor responses to this maneuver are blocked by nifedipine and diltiazem.^{9 31} In contrast with the behavior of nonrenal vascular beds,^{6 32 33 34} tyrosine kinase blockade did not alter K⁺-induced afferent arteriolar constriction in the present study. This observation has several mechanistic implications. First, the effect of AG18 on Ang II responsiveness cannot be attributed to a direct (tyrosine kinase–independent) effect of AG18 on the L-type Ca²⁺ channel. Second, it is also unlikely that a direct effect of AG18 on the contractile apparatus or on the Ca²⁺ sensitivity of the contractile proteins^{35 36} underlies the impact of this compound on Ang II responsiveness. Finally, it unlikely that either membrane depolarization or the resulting Ca²⁺ influx initiates the tyrosine kinase activation involved in the afferent arteriolar Ang II signaling. However, we cannot rule out the possibility that the relatively large transient increase in intracellular [Ca²⁺] resulting from Ang II–induced Ca²⁺ mobilization triggers tyrosine kinase activation.

In recent years, it has become clear that activation of various G-protein–coupled receptors (such as the AT₁ receptor) rapidly induces transactivation of the EGF receptor and that inhibition of EGF receptor tyrosine kinase activity prevents the subsequent events that lead to MAP kinase activation and transmission of mitogenic signals to the nucleus.³⁷ AT₁-EGF receptor cross-talk has been studied primarily in the context of the mitogenic effect of Ang II on aortic myocytes. Although the present study does not address the sequence of events linking AT₁ receptor activation and tyrosine kinase activity to evoke renal arteriolar constriction, involvement of the EGF receptor tyrosine kinase is indicated by the ability of AG1478 to attenuate renal arteriolar constrictor responses to Ang II. These observations provide evidence of cross-talk between the AT₁ receptor and the EGF receptor in both afferent and efferent arterioles, despite differences in other aspects of Ang II–induced signaling at these sites. For example, although Ang II has been suggested to constrict afferent arterioles through G_q and efferent arterioles through G_i,¹⁹ both of these G proteins are capable of using Src to phosphorylate the EGF receptor for recruitment of adaptor proteins and MAP kinase activation.³⁸ Some studies that used cultured rat vascular smooth muscle suggest that Src family tyrosine kinases mediate Ang II–induced phosphorylation of PLC-, resulting in IP₃ formation and Ca²⁺ mobilization.^{2 39} Alternatively, Ang II may trigger G_q-mediated PLC-ß activation, with the resulting Ca²⁺ mobilization triggering EGF receptor transactivation and phosphorylation by Src.^{4 40} The involvement of PLC-ß or PLC- may represent a critical distinction between these two scenarios; however, although PLC is involved in Ang II–induced signaling in both afferent and efferent arterioles, the role of specific PLC isoforms has not been evaluated. Hence, further investigation is necessary to elucidate the mechanism(s) linking the AT₁ receptor to tyrosine kinase activation in the afferent and efferent arterioles as well as the mechanism through which EGF receptor activation influences contractile tone.

Summary
A broad-spectrum tyrosine kinase inhibitor attenuated Ang II responsiveness in both afferent and efferent arterioles but did not significantly alter afferent arteriolar constrictor responses to KCl-induced depolarization. Afferent and efferent arteriolar constrictor responses to Ang II were also diminished by an EGF receptor tyrosine kinase inhibitor. These observations suggest that tyrosine phosphorylation event(s) contribute to Ang II–induced vasoconstrictor signaling in the renal microvasculature and that this process involves the EGF receptor tyrosine kinase. Further studies are required to determine if tyrosine phosphorylation is a critical step mediating Ang II–induced renal arteriolar constriction or, alternatively, if tyrosine kinase activity exerts a modulatory influence on Ang II responsiveness.

	Acknowledgments

 
This work was supported by the National Institutes of Health (DK39202). Merck Sharp and Dohme Research Laboratories (Rahway, NJ) provided enalaprilat for use in these studies.

Received October 25, 2000; first decision November 27, 2000; accepted December 11, 2000.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Marrero MB, Schieffer B, Ma HP, Bernstein KE, Ling BN. ANG II-induced tyrosine phosphorylation stimulates phospholipase C-1 and Cl^- channels in mesangial cells. Am J Physiol Cell Physiol. 1996;270:C1834–C1842.[Abstract/Free Full Text]

2. Marrero MB, Paxton WG, Duff JL, Berk BC, Bernstein KE. Angiotensin II stimulates tyrosine phosphorylation of phospholipase C-1 in vascular smooth muscle cells. J Biol Chem. 1994;269:10935–10939.[Abstract/Free Full Text]

3. Bokemeyer D, Schmitz U, Kramer HJ. Angiotensin II-induced growth of vascular smooth muscle cells requires an Src-dependent activation of the epidermal growth factor receptor. Kidney Int. 2000;58:549–558.[Medline] [Order article via Infotrieve]

4. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H, Motley ED, Kawakatsu H, Owada KM, Hirata Y, Marumo F, Inagami T. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem. 1998;273:8890–8896.[Abstract/Free Full Text]

5. Meloche S, Landry J, Huot J, Houle F, Marceau F, Giasson E. p38 MAP kinase pathway regulates angiotensin II-induced contraction of rat vascular smooth muscle. Am J Physiol Heart Circ Physiol. 2000;279:H741-H751.[Abstract/Free Full Text]

6. Watts SW, Florian JA, Monroe KM. Dissociation of angiotensin II-stimulated activation of mitogen-activated protein kinase kinase from vascular contraction. J Pharmacol Exp Ther. 1998;286:1431–1438.[Abstract/Free Full Text]

7. Liu H, Sperelakis N. Tyrosine kinases modulate the activity of single L-type calcium channels in vascular smooth muscle cells from rat portal vein. Can J Physiol Pharmacol. 1997;75:1063–1068.[Medline] [Order article via Infotrieve]

8. Carmines PK, Navar LG. Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. Am J Physiol Renal Fluid Electrolyte Physiol. 1989;256:F1015–F1020.[Abstract/Free Full Text]

9. Carmines PK, Fowler BC, Bell PD. Segmentally distinct effects of depolarization on intracellular [Ca²⁺] in renal arterioles. Am J Physiol Renal Fluid Electrolyte Physiol. 1993;265:F677–F685.[Abstract/Free Full Text]

10. Loutzenhiser R, Hayashi K, Epstein M. Divergent effects of KCl-induced depolarization on afferent and efferent arterioles. Am J Physiol Renal Fluid Electrolyte Physiol. 1989;257:F561–F564.[Abstract/Free Full Text]

11. Loutzenhiser K, Loutzenhiser R. Angiotensin II–induced Ca²⁺ influx in renal afferent and efferent arterioles: differing roles of voltage-gated and store-operated Ca²⁺ entry. Circ Res. 2000;87:551–557.[Abstract/Free Full Text]

12. Casellas D, Navar LG. In vitro perfusion of juxtamedullary nephrons in rats. Am J Physiol Renal Fluid Electrolyte Physiol. 1984;246:F349–F358.[Abstract/Free Full Text]

13. Ohishi K, Carmines PK, Inscho EW, Navar LG. EDRF-angiotensin II interactions in rat juxtamedullary afferent and efferent arterioles. Am J Physiol Renal Fluid Electrolyte Physiol. 1992;263:F900–F906.[Abstract/Free Full Text]

14. Ikenaga H, Fallet RW, Carmines PK. Contribution of tubuloglomerular feedback to renal arteriolar angiotensin II responsiveness. Kidney Int. 1996;49:34–39.[Medline] [Order article via Infotrieve]

15. Ito S, Amin J, Ren YL, Arima S, Abe K, Carretero OA. Heterogeneity of angiotensin action in renal circulation. Kidney Int. 1997;52:S128–S131.

16. Harrison-Bernard LM, Carmines PK. Juxtamedullary microvascular responses to arginine vasopressin in rat kidney. Am J Physiol. 1994;267:F249–F256.[Abstract/Free Full Text]

17. Ikenaga H, Bast JP, Fallet RW, Carmines PK. Exaggerated impact of ATP-sensitive K⁺ channels on afferent arteriolar diameter in diabetes mellitus. J Am Soc Nephrol. 2000;11:1199–1207.[Abstract/Free Full Text]

18. Loutzenhiser R, Epstein M, Hayashi K, Takenaka T, Forster H. Characterization of the renal microvascular effects of angiotensin II antagonist, DuP 753: studies in isolated perfused hydronephrotic kidneys. Am J Hypertens. 1991;4:309S-314S.[Medline] [Order article via Infotrieve]

19. Takenaka T, Suzuki H, Fujiwara K, Kanno Y, Ohno Y, Hayashi K, Nagahama T, Saruta T. Cellular mechanisms mediating rat renal microvascular constriction by angiotensin II. J Clin Invest. 1997;100:2107–2114.[Medline] [Order article via Infotrieve]

20. Casellas D, Carmines PK. Control of the renal microvasculature: cellular and integrative perspectives. Curr Opin Nephrol Hypertens. 1996;5:57–63.[Medline] [Order article via Infotrieve]

21. Bilder GE, Krawiec JA, McVety K, Gazit A, Gilon C, Lyall R, Zilberstein A, Levitzki A, Perrone MH, Schreiber AB. Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am J Physiol Cell Physiol. 1991;260:C721–C730.[Abstract/Free Full Text]

22. Levitzki A, Gilon S. Tyrphostins as molecular tools and potential antiproliferative drugs. Trends Pharmacol Sci. 1991;12:171–174.[Medline] [Order article via Infotrieve]

23. Lyall RM, Zilberstein A, Gazit A, Gilon C, Levitzki A, Schlessinger J. Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J Biol Chem. 1989;264:14503–14509.[Abstract/Free Full Text]

24. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 1995;267:1782–1788.[Abstract/Free Full Text]

25. Gazit A, Yaish P, Gilon C, Levitzki A. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989;32:2344–2352.[Medline] [Order article via Infotrieve]

26. Touyz RM, Schiffrin EL. Angiotensin II regulates vascular smooth muscle cell pH, contraction, and growth via tyrosine kinase-dependent signaling pathways. Hypertension. 1997;30:222–229.[Abstract/Free Full Text]

27. Touyz RM, Schiffrin EL. Tyrosine kinase signaling pathways modulate angiotensin II- induced calcium ([Ca²⁺]_i) transients in vascular smooth muscle cells. Hypertension. 1996;27:1097–1103.[Abstract/Free Full Text]

28. Malloy LG, Sauro MD. Tyrosine kinase inhibition suppresses angiotensin contraction in hypertensive and normotensive small resistance arteries. Life Sci. 1996;58:PL317-PL324.[Medline] [Order article via Infotrieve]

29. Wijetunge S, Hughes AD. Effect of platelet-derived growth factor on voltage-operated calcium channels in rabbit isolated ear artery cells. Br J Pharmacol. 2000;115:534–538.[Medline] [Order article via Infotrieve]

30. Wijetunge S, Aalkjaer C, Schachter M, Hughes AD. Tyrosine kinase inhibitors block calcium channel currents in vascular smooth muscle cells. Biochem Biophys Res Commun. 1992;189:1620–1623.[Medline] [Order article via Infotrieve]

31. Carmines PK, Ohishi K, Ikenaga H. Functional impairment of renal afferent arteriolar voltage-gated calcium channels in rats with diabetes mellitus. J Clin Invest. 1996;98:2564–2571.[Medline] [Order article via Infotrieve]

32. Masumoto N, Nakayama K, Oyabe A, Uchino M, Ishii K, Obara K, Tanabe Y. Specific attenuation of the pressure-induced contraction of rat cerebral artery by herbimycin A. Eur J Pharmacol. 1997;330:55–63.[Medline] [Order article via Infotrieve]

33. Watts SW, Yeum CH, Campbell G, Webb RC. Serotonin stimulates protein tyrosyl phosphorylation and vascular contraction via tyrosine kinase. J Vasc Res. 1996;33:288–298.[Medline] [Order article via Infotrieve]

34. Gould EM, Rembold CM, Murphy RA. Genistein, a tyrosine kinase inhibitor, reduces Ca²⁺ mobilization in swine carotid media. Am J Physiol Cell Physiol. 1995;268:C1425–C1429.[Abstract/Free Full Text]

35. Ohanian J, Ohanian V, Shaw L, Bruce C, Heagerty AM. Involvement of tyrosine phosphorylation in endothelin-1-induced calcium-sensitization in rat small mesenteric arteries. Br J Pharmacol. 1997;120:653–661.[Medline] [Order article via Infotrieve]

36. Di Salvo J, Pfitzer G, Semenchuk LA. Protein tyrosine phosphorylation, cellular Ca²⁺, and Ca ²⁺ sensitivity for contraction of smooth muscle. Can J Physiol Pharmacol. 1994;72:1434–1439.[Medline] [Order article via Infotrieve]

37. Harris RC. EGF receptor activation by G-protein coupled receptors. Kidney Int. 2000;58:898–899.[Medline] [Order article via Infotrieve]

38. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A. Signal characteristics of G protein-transactivated EGF receptor. EMBO J. 1997;16:7032–7044.[Medline] [Order article via Infotrieve]

39. Marrero MB, Schieffer B, Paxton WG, Schieffer E, Bernstein KE. Electroporation of pp60^c-src antibodies inhibits the angiotensin II activation of phospholipase C-g1 in rat aortic smooth muscle cells. J Biol Chem. 1995;270:15734–15738.[Abstract/Free Full Text]

40. Inagami T, Eguchi S, Numaguchi K, Motley ED, Tao H, Matsumoto T, Yamakawa T. Cross-talk between angiotensin II receptors and the tyrosine kinases and phosphatases. J Am Soc Nephrol. 1999;10:S57–S61.

This article has been cited by other articles:

				C. S. Escano Jr., L. B. Keever, A. A. Gutweiler, and B. T. Andresen Angiotensin II Activates Extracellular Signal-Regulated Kinase Independently of Receptor Tyrosine Kinases in Renal Smooth Muscle Cells: Implications for Blood Pressure Regulation J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 34 - 42. [Abstract] [Full Text] [PDF]

				W.-Z. Ying, H.-G. Zhang, and P. W. Sanders EGF Receptor Activity Modulates Apoptosis Induced by Inhibition of the Proteasome of Vascular Smooth Muscle Cells J. Am. Soc. Nephrol., January 1, 2007; 18(1): 131 - 142. [Abstract] [Full Text] [PDF]

				W.-Z. Ying and P. W. Sanders Enhanced expression of EGF receptor in a model of salt-sensitive hypertension Am J Physiol Renal Physiol, August 1, 2005; 289(2): F314 - F321. [Abstract] [Full Text] [PDF]

				Q. Che and P. K. Carmines Src family kinase involvement in rat preglomerular microvascular contractile and [Ca2+]i responses to ANG II Am J Physiol Renal Physiol, April 1, 2005; 288(4): F658 - F664. [Abstract] [Full Text] [PDF]

				M. Salomonsson and W. J. Arendshorst Effect of tyrosine kinase blockade on norepinephrine-induced cytosolic calcium response in rat afferent arterioles Am J Physiol Renal Physiol, May 1, 2004; 286(5): F866 - F874. [Abstract] [Full Text] [PDF]

				D. K. Rohra, T. Yamakuni, K.-I. Furukawa, N. Ishii, T. Shinkawa, T. Isobe, and Y. Ohizumi Stimulated Tyrosine Phosphorylation of Phosphatidylinositol 3-Kinase Causes Acidic pH-Induced Contraction in Spontaneously Hypertensive Rat Aorta J. Pharmacol. Exp. Ther., December 1, 2002; 303(3): 1255 - 1264. [Abstract] [Full Text] [PDF]

				Q. Che and P. K. Carmines Angiotensin II Triggers EGFR Tyrosine Kinase-Dependent Ca2+ Influx in Afferent Arterioles Hypertension, November 1, 2002; 40(5): 700 - 706. [Abstract] [Full Text] [PDF]

				R. W. Carter and N. L. Kanagy Tyrosine kinases regulate intracellular calcium during alpha 2-adrenergic contraction in rat aorta Am J Physiol Heart Circ Physiol, October 1, 2002; 283(4): H1673 - H1680. [Abstract] [Full Text] [PDF]

				S. Kagiyama, S. Eguchi, G. D. Frank, T. Inagami, Y. C. Zhang, and M. I. Phillips Angiotensin II-Induced Cardiac Hypertrophy and Hypertension Are Attenuated by Epidermal Growth Factor Receptor Antisense Circulation, August 20, 2002; 106(8): 909 - 912. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carmines, P. K. Articles by Fujiwara, K. Search for Related Content PubMed PubMed Citation Articles by Carmines, P. K. Articles by Fujiwara, K. Related Collections ACE/Angiotension receptors Cell signalling/signal transduction Growth factors/cytokines Other Vascular biology